HomeNDC LookupRxCUI directory › RxCUI 197412

Bromocriptine 5 MG Oral Capsule — RxCUI 197412

RxNorm drug concept · Semantic clinical drug
RxCUI 197412 Semantic clinical drug · SCD ● Current RxNorm concept 5 FDA products 10 package NDCs Snapshot Jul 14, 2026

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI197412
Official nameBromocriptine 5 MG Oral Capsule
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
Also known asbromocriptine 5 MG (as bromocriptine mesylate 5.74 MG) Oral Capsule; bromocriptine mesylate 5 MG Oral Capsule
FDA products mapped5
Package NDCs mapped10
Reported Medicaid activity (SDUD)3,253 prescriptions · 20 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Bromocriptine: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • It's really important to take it with food — a large number of people vomit when they take bromocriptine on an empty stomach. Food helps your stomach tolerate it much better. If yo...
  • Why do I have to take bromocriptine with food? Can I just take it on an empty stomach if I forget?
  • Yes, dizziness when you stand up is one of the most common early side effects — it's called orthostatic hypotension, where your blood pressure drops briefly with position changes....
  • I feel dizzy when I stand up after starting this medication. Is that normal, and will it go away?
📖 Read our full Bromocriptine guide →

🕸️ Concept Web — How Bromocriptine 5 MG Oral Capsule Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Bromocriptine 5 MG Oral Capsule RxCUI 197412

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Bromocriptine 1760
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Parlodel 38
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Bromocriptine Oral Capsule 371127
    • Bromocriptine Oral Product 1155381
    • Bromocriptine Pill 1155382
    • Bromocriptine Oral Capsule [Parlodel] 366490
    • Parlodel Oral Product 1182381
    • Parlodel Pill 1182382
    • Oral Capsule 316965
    • Oral Product 1151131
    • +1 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

    • Bromocriptine 5 MG 329606
    • Bromocriptine 5 MG Oral Capsule [Parlodel] 105050
    • Bromocriptine 5 MG [Parlodel] 563894

Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Bromocriptine 5 MG SCDC · 329606
  • Bromocriptine Oral Capsule SCDF · 371127
  • Bromocriptine Oral Product SCDG · 1155381
  • Bromocriptine Pill SCDG · 1155382

Brand-Name Concepts

  • Bromocriptine 5 MG Oral Capsule [Parlodel] SBD · 105050
  • Bromocriptine 5 MG [Parlodel] SBDC · 563894
  • Bromocriptine Oral Capsule [Parlodel] SBDF · 366490
  • Parlodel Oral Product SBDG · 1182381
  • Parlodel Pill SBDG · 1182382
  • Parlodel BN · 38

📦 FDA Products & Package NDCs

5 products · 10 package NDCs
10 package NDCs map to RxCUI 197412 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
00378-7096-01 100 CAPSULE in 1 BOTTLE, UNIT-DOSE (0378-7096-01) Bromocriptine Mesylate Mylan Pharmaceuticals Inc. 2013-07-01
00378-7096-93 30 CAPSULE in 1 BOTTLE, UNIT-DOSE (0378-7096-93) Bromocriptine Mesylate Mylan Pharmaceuticals Inc. 2013-06-17
65841-0654-01 100 CAPSULE in 1 BOTTLE (65841-654-01) Bromocriptine mesylate Zydus Lifesciences Limited 2009-01-23
65841-0654-06 30 CAPSULE in 1 BOTTLE (65841-654-06) Bromocriptine mesylate Zydus Lifesciences Limited 2009-01-23
68382-0110-01 100 CAPSULE in 1 BOTTLE (68382-110-01) Bromocriptine mesylate Zydus Pharmaceuticals USA Inc. 2009-01-23
68382-0110-06 30 CAPSULE in 1 BOTTLE (68382-110-06) Bromocriptine mesylate Zydus Pharmaceuticals USA Inc. 2009-01-23
70954-0951-10 30 CAPSULE in 1 BOTTLE (70954-951-10) Bromocriptine Mesylate ANI Pharmaceuticals, Inc. 2026-04-06
70954-0951-20 100 CAPSULE in 1 BOTTLE (70954-951-20) Bromocriptine Mesylate ANI Pharmaceuticals, Inc. 2026-04-06
70954-0978-10 30 TABLET in 1 BOTTLE (70954-978-10) Bromocriptine Mesylate ANI Pharmaceuticals, Inc. 2025-06-15
70954-0978-20 100 TABLET in 1 BOTTLE (70954-978-20) Bromocriptine Mesylate ANI Pharmaceuticals, Inc. 2025-06-15
Observed labelers: ANI Pharmaceuticals, Inc. (4) · Mylan Pharmaceuticals Inc. (2) · Zydus Lifesciences Limited (2) · Zydus Pharmaceuticals USA Inc. (2) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.